Core Viewpoint - Nektar Therapeutics (NKTR) has experienced significant selling pressure, resulting in a 38.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Stock Performance and Technical Indicators - NKTR's stock is currently in oversold territory, with an RSI reading of 28.23, suggesting that the heavy selling may be exhausting itself and a price reversal could occur soon [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30, indicating potential entry opportunities for investors [2][3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for NKTR, resulting in a 0.5% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6]. - NKTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Viewpoint - Nektar Therapeutics (NKTR) has experienced a decline of 11.5% in its stock price over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick suggesting that the stock may have found support after a downtrend [3][4]. - This pattern typically signals that bears may have lost control, indicating a potential trend reversal when it occurs at the bottom of a downtrend [4]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding NKTR's future earnings, with a 0.1% increase in the consensus EPS estimate over the last 30 days, indicating agreement on the company's potential for better earnings [6][7]. - NKTR holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperforms the market [8].

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed ...

When I wrote about Nektar Therapeutics (NASDAQ: NKTR ) in April, a major focus of discussion was rezpegaldesleukin and trials of the drug in atopic dermatitis and alopecia areata. Since those trials won't produce data until 2025, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s D ...

Nektar Therapeutics (NKTR) incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents.In the year-ago quarter, the company reported an adjusted (excluding non-cash restructuring and impairment charges) loss of 18 cents.Total revenues remained flat year over year at $24.1 million. The reported figure beat the Zacks Consensus Estimate of $16 million.See the Zacks Earnings Calendar to stay ahead of market-making news. NKTR’s Q3 Results i ...

Financial Data and Key Metrics Changes - The company ended Q3 2024 with $249 million in cash and investments, with no debt on the balance sheet [46] - Revenue for Q3 2024 was $24.1 million, with full-year revenue expected to be between $90 million and $95 million [48] - The company anticipates ending 2024 with approximately $265 million in cash and investments, extending the cash runway into Q4 2026 [47][49] Business Line Data and Key Metrics Changes - The lead asset, rezpegaldesleukin (REZPEG), is advancing in Phase 2 studies for atopic dermatitis and alopecia areata, with enrollment on track [10][11] - The company is also advancing NKTR-165, a TNFR2 agonist antibody program, with IND submission planned for the second half of 2025 [13][34] - NKTR-255, an IL15 program in oncology, has shown promising data in enhancing CAR-T therapies and is being evaluated in multiple studies [16][41] Market Data and Key Metrics Changes - There are approximately 15 million people with moderate to severe atopic dermatitis in the USA, with less than 10% currently receiving biologics [9] - Nearly 7 million people in the U.S. are affected by alopecia areata, highlighting a significant unmet medical need for new therapies [11] Company Strategy and Development Direction - The company is focused on advancing its immunology and inflammation pipeline, particularly through REZPEG and NKTR-165 [7][13] - A strategic divestiture of the PEGylation reagent manufacturing facility aims to streamline operations and strengthen financial position [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of REZPEG in treating atopic dermatitis and alopecia areata, citing promising early data [8][10] - The company is committed to advancing its pipeline and expects to provide updates on progress, particularly regarding upcoming data readouts in 2025 [82] Other Important Information - The company plans to recognize a gain of approximately $40 million to $45 million upon the sale of the Huntsville manufacturing facility [49] - R&D expenses for Q3 2024 were $35 million, with full-year R&D expenses expected to range between $120 million and $130 million [49] Q&A Session Summary Question: Can you quantify how close the studies for atopic dermatitis and alopecia areata are to completion? - Management indicated that enrollment is progressing well and will update the status on clinicaltrials.gov once completed [54] Question: What is the protocol regarding corticosteroid use in the Phase 2b atopic dermatitis trial? - Patients must wash out from topical corticosteroids before enrollment and are not permitted to use them during the study [59][60] Question: Can you provide details on the patient baseline characteristics in the REZPEG AD trial? - Management stated that the study is fully blinded, and detailed baseline characteristics will be provided in the top-line data [63] Question: What are the expected outcomes from the NKTR-255 studies? - Data presented showed significant improvements in lymphocyte counts and potential benefits in patients with severe lymphopenia [74][76] Question: After the 36-week maintenance period in the AD study, will patients continue treatment? - Patients will be followed for one year after treatment without further medication to assess remission effects [78]

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value ...

Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO, November 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth qu ...

SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024.Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026."We made excellent progress this quarter advancing our I&I pipeline, ...